BECAS
ELEAN Mariano Daniel
artículos
Título:
Soymilk-fermented with Lactobacillus delbrueckii subsp. delbrueckii TUA4408L improves immune-health in pigs
Autor/es:
SUDA, Y.; KAGAWA, K.; FUKUYAMA, K.; ELEAN, M.; ZHOU, B.; TOMOKIYO, M.; ISLAM, M. AMINUL; RAJOKA, M.S.R.; KOBER, A.K.M. HUMAYUN; SHIMAZU, T.; EGUSA, S.; TERASHIMA, Y.; ASO, H.; IKEDA-OHTSUBO, W.; VILLENA, J.; KITAZAWA, H.
Revista:
Beneficial Microbes
Editorial:
Wageningen Academic Publishers
Referencias:
Año: 2022 p. 1 - 12
ISSN:
1876-2883
Resumen:
Lactobacillus delbrueckii subsp. delbrueckii TUA4408L has the ability to grow and ferment soymilk and is able to modulate the innate immune response of intestinal epithelial cells in vitro. These two properties prompt us to evaluate whether the soymilk fermented with the TUA4408L strain can induce beneficial immunomodulatory effects in vivo. For this purpose, pigs were selected as a preclinical model. The studies performed here demonstrated that the L. delbrueckii subsp. delbrueckii TUA4408L-fermented soymilk (TUA4408L FSM) reduced blood markers of inflammation and differentially regulated the expression of inflammatory and regulatory cytokines in the intestinalmucosa. These immunological changes induced by the TUA4408L FSM were associated to an enhanced resistance to pathogenic Escherichia coli and an improved grow performance and meat quality of pigs. The experiments and analysis in our study indicate that the immunobiotic TUA4408L FSM could be an interesting non-dairy functional food to beneficially modulate the intestinal immune system, improve protection against pathogens and reduce inflammatory damage. The preclinical study carried out here in pigs could have a better correlation in humans, compared to a rodent model. However, the clinical relevance of these findings still needs to be confirmed by furtherresearch, for example, in controlled human challenge studies.